The US Food and Drug Administration (FDA) has cleared Arteriocyte Medical Systems' 50cc volume of Anticoagulant Citrate Dextrose Solution, USP (ACD-A) for use with its Magellan Platelet Separation system.
The Magellan system utilizes the company's Magellan MAR01 technology to produce platelet rich plasma from blood and bone marrow, while hematopoietic stem cells and mesenchymal stem cells from bone marrow in as little as fifteen minutes.
The platelet rich plasma facilitates physicians to improve surgical outcomes and help patients heal faster.
The company's portfolio of products also include 30cc volume ACD-A vials designed for use with its Magellan surgical convenience kits.
Arteriocyte is involved in distributing medical devices and point of care surgical solutions to address serious unmet medical needs in cardiac, orthopedic and vascular surgeries.
